1. Home
  2. ABLV vs CALC Comparison

ABLV vs CALC Comparison

Compare ABLV & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

N/A

Current Price

$0.64

Market Cap

31.4M

Sector

N/A

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.56

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
CALC
Founded
2015
2011
Country
China
United States
Employees
89
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.4M
88.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ABLV
CALC
Price
$0.64
$0.56
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.4K
421.5K
Earning Date
04-23-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$0.46
52 Week High
$1.77
$7.20

Technical Indicators

Market Signals
Indicator
ABLV
CALC
Relative Strength Index (RSI) 43.40 32.66
Support Level $0.60 $0.49
Resistance Level $0.73 $0.79
Average True Range (ATR) 0.03 0.08
MACD -0.00 0.04
Stochastic Oscillator 25.75 11.52

Price Performance

Historical Comparison
ABLV
CALC

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: